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OBJECTIVES: Radiation-induced nausea and vomiting (RINV) is commonly experi-
enced by cancer patients undergoing radiation treatment. Current NCCN guide-
lines recommend the use of the 5-hydroxytryptamine-3 serotonin receptor antag-
onists (5-HT3-RAs) for the prevention and treatment of RINV. The purpose of this
study was to examine the incidence of 5-HT3-RA utilization and subsequent RINV,
in patients diagnosed with colon cancer and undergoing radiation treatment.
METHODS: This was a retrospective analysis using HIPAA-compliant medical and
pharmacy claims in a commercially-insured U.S. patient population. The study
identified continuously enrolled adult patients diagnosed with colon cancer who
received radiation treatment during the period from 4/1/2007 to 8/31/2009. Patients
receiving combination chemotherapy were excluded. The index date was the date
of initiation of radiation treatment and patients were followed for 30 days. Prophy-
lactic administration of a 5-HT3-RA was defined by medication on the day of or the
day prior to radiation therapy. The incidence of RINV was calculated from medical
claims for an outpatient appointment, inpatient admission, or ER visit with a pri-
mary diagnosis of RINV. RESULTS: A total of 2,400 patients were identified as
meeting the inclusion and exclusion criteria for the study. Average age of patients
was 57.6 years old and 43.8% were female. Radiation therapy included localized
treatment (48.6%), total body irradiation (30.9%), or both (20.5%). Of the patients
identified, 73.9% received no 5-HT3-RA, 5.0% were treated prophylactically, and
21.1% received a 5-HT3-RA in the days after radiation therapy. Of the patients who
received the 5-HT3-RA prophylactically, 58.2% were treated with an oral formula-
tion. Incidence of subsequent RINV for all patients, independent of rescue medica-
tion use, was 15.2%. CONCLUSIONS: The results showed use of the 5-HT3-RA an-
tiemetics in patients undergoing radiation treatment for colon cancer was
uncommon and prophylactic administration was relatively rare.
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OBJECTIVES: To determine the number of patients with diagnosed acute myeloid
leukaemia (AML) including chemotherapy rates, types and care settings using sick-
fund data. METHODS: Data provided by 4 statutory sick funds (SHI) and 2 data
providers were analyzed for 2010. AML diagnosis was identified by ICD-10 C92.0
and other types of cancer by ICD-10 C00-79; D00-09; D37-48. Prevalence was extrap-
olated to the German population by correcting for a representative age- and gender
distribution. RESULTS: The median proportion of AML patients  60 years was
61.1% or 6,590 patients (SHI A: 63.0% 4,938; B: 50.9% 5,858; C: 68.9% 8,975). The
proportion of AML patients  65 years (sick fund D) was 47.6% or 4,400 patients.
Gender ratio was 57% male and 43% female. On average, 2 additional oncological
disorders were found in 77% of AML patients. 50% had an unspecified leukaemia
(C95.90), 25% had CML (C92.1*) and 20% MDS (D46.9). Among patients65 years the
rate of treatment was 60.9% (Anatomical Therapeutic Chemical (ATC) Code L01*
(40%), pharmacy number (PZN) 9999092 (19%), operating and procedure code (OPS)
854* (26%)). 16.4% received both out- and inpatient treatment, 34.5% received out-
patient treatment and 10.0% inpatient treatment. Identification of comppunds was
possible when ATC codes were reported. 63.6% received imatinib and/or hydroxy-
carbamide, 11.4% tioguanine, 9.1% mercaptopurine, 9.1% cytarabine and 6.8% re-
ceived dasatinib. The outpatient treatment rate in patients  60 years diagnosed
with AML only was 34.3% (6,2% mercaptopurine and idarubicine, 28.1% PZN
9999092). CONCLUSIONS: Prevalence was higher than previously reported inci-
dence numbers of 3,100 AML patients (SHI, all age groups). The yearly outpatient
treatment rate was relatively low with 34.3% in patients diagnosed with AML alone.
Other oncological disorders are likely to be diagnosed before AML diagnosis could
be confirmed. Treatment rates increased with additional oncological disorders
with the use of substances not approved for AML.
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OBJECTIVES: Panitumumab plus FOLFOX significantly improved progression-free
survival (PFS) in patients with WT KRAS mCRC. The objective of this analysis was to
use the quality-adjusted time without symptoms of disease or toxicity of treatment
(Q-TWiST) method to compare quality-adjusted survival between the treatment
arms. METHODS: Patients with mCRC were randomized to panitumumab plus
FOLFOX or FOLFOX alone in a phase III clinical trial. For each treatment arm, the
area under the survival curve, which was estimated using the Weibull distribution,
was partitioned into health states: toxicity (TOX), time without symptoms of dis-
ease progression or toxicity (TWiST, i.e., PFS minus TOX), and relapse period (REL,
i.e., overall survival (OS) minus PFS); and adjusted using utility weights derived
from patient-reported EuroQoL 5-dimensions measures. The null hypothesis of no
difference between treatment groups was tested based on the normal approxima-
tion with standard errors calculated by the bootstrap method. Sensitivity analyses
were performed using the standard Q-TWiST approach with means restricted to
median OS. RESULTS: Of 1,183 patients who were randomly assigned, 1,096 pa-
tients (93%) had available tumor KRAS status, of which 656 patients (60%) had WT
KRAS tumors (panitumumab plus FOLFOX, n325; FOLFOX alone, n331) and were
included in this analysis. Compared to patients treated with FOLFOX alone, the
panitumumab plus FOLFOX group had significantly longer quality-adjusted PFS
(8.5 versus 7.2 months, respectively; 1.3 additional quality-adjusted months; p 
0.02) and quality-adjusted OS (22.4 versus 18.6 months; 3.8 additional quality-ad-
justed months; p 0.04). When analysis was restricted to 24 months follow-up, the
Q-TWiST advantage was smaller but still significant (14.0 versus 13.0 months; 1.0
additional quality-adjusted month; p  0.04). CONCLUSIONS: This Q-TWiST anal-
ysis showed that in patients with previously untreated WT KRAS mCRC, panitu-
mumab plus FOLFOX significantly improved the duration of the quality-adjusted
survival compared with FOLFOX alone.
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OBJECTIVES: About a decade ago, the introduction of the tyrosine kinase inhibitor
(TKI) imatinib dramatically extended the life span of chronic myeloid leukemia
(CML) patients. Currently, there are several different TKIs approved for CML treat-
ment. The goal of this study is to develop a clinical decision-analytic model for the
evaluation of the comparative long-term effectiveness of first-line therapy for CML
within the Austrian health care context.METHODS:We developed a Markov state-
transition model for patients in the chronic-phase of CML treated with first-line TKI
imatinib, dasatinib or nilotinib. Seven different strategies including different com-
binations of first and second-generation TKIs as well as chemotherapy or stem cell
transplantation were evaluated. The model was parameterized using published
trial data, data from the Austrian CML registry and from an Austrian CML expert
panel. The model was analyzed as a cohort simulation over a lifelong time horizon.
Health outcomes evaluated were life-years (LYs) gained and quality-adjusted life
years (QALYs) gained. Deterministic and structural sensitivity analyses were
performed. RESULTS: Nilotinib followed by dasatinib after failure is the most ef-
fective treatment in terms of both LYs gained (19.71 LY) and QALYs gained (17.08
QALYs). All strategies including a second-line TKI were superior compared to strat-
egies without second-line TKI. Deterministic sensitivity analyses showed that the
ranking of the strategies was mostly influenced by the duration of first- and sec-
ond-line therapies. In a structural sensitivity analysis, where patients move di-
rectly from second-line TKI therapy to advanced stage of disease, strategies with-
out second-line therapy are most effective. CONCLUSIONS: Based on our analyses
results, the most clinically effective strategy is nilotinib followed by dasatinib as
second-line therapy. All three TKIs are approved as first-line therapy in Austria.
Our results may support clinicians and patients in their decision making.
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OBJECTIVES: A combination Cabazitaxel plus Corticosteroids (CC) has been shown
to prolong survival in patients with mHRPC versus Mitoxantrone plus Corticoste-
roids (MC) in the TROPIC study of patients with mHRPC. As there is no direct
comparison CC vs. Corticosteroids (C) as requested by the German regulatory bod-
ies we aimed to provide an indirect comparison.METHODS:A systematic search of
the DIMDI database was conducted in 12/2011. Data were combined using meta-
analyses and indirect comparisons (“Bucher et al. J Clin Oncol 2008”). The end-
points analysed were all cause mortality overall and in patients with or without
pain and pain response (Hazard/Response Ratios with 95%-confidence intervals).
RESULTS: A total of 168 potential publications resulted in three relevant studies
(Berry, 2002; Kantoff, 1999; Tannock, 1996) for MC vs. C. A meta-analysis of mortal-
ity in the three studies resulted in HR0.92 (95%-CI 0.74-1.13) for MC vs. C. Com-
bined with TROPIC (CC vs. MC 0.70; 0.59-0.83) the indirect comparison (CC vs. C)
resulted in HR0.64 (0.49-0.84). For mortality in patients without pain at baseline,
the HR for MC vs. C was 0.89 (0.59-1.34) (Berry). The indirect comparison CC vs. C
resulted in HR0.51 (0.30-0.84) using TROPIC patients without pain (HR0.57; 0.42-
0.77). For mortality in patients with pain at baseline, the HR for MC vs. C was 0.83
(0.60-1.16) (Tannock). The indirect comparison CC vs. C resulted in HR0.65 (0.43-
0.98) using TROPIC patients with pain (HR0.78; 0.60-1.00). In patients with pain at
baseline, pain response was higher with MC vs. C (RR2.33; 1.19-4.57) (Tannock).
The indirect comparison CC vs. C resulted in RR2.77 (1.05-7.32) using TROPIC
patients with pain (RR1.19; 0.59-2.39). CONCLUSIONS: The analyses indicate a
statistically significant reduction of mortality in patients with mHRPC receiving CC
vs. C with or without pain and an increased pain response.
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